Search Results - "Issler, Eran"

21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients by Harel, Michal, Lahav, Coren, Jacob, Eyal, Issler, Eran, Bar, Haim, Dicker, Adam, Sharon, Ofer, Bacchiocchi, Antonietta, Halaban, Ruth, Sznol, Mario, Shaked, Yuval

“…BackgroundIn recent years, studies have indicated that in response to almost any type of anti-cancer therapy, the patient (the host) may generate…”
Get full text

The host response to immune checkpoint inhibitors: From mechanisms to therapeutic implications by Fremder, Ella, Jacob, Eyal, Khononov, Irena, Issler, Eran, Raveh, Shani, Dahan, Nili, Bar, Haim, Shaked, Yuval

“…Abstract only e14584 Background: One of the major challenges in clinical immuno-oncology today is predicting which patients will respond to treatment. Although…”
Get full text

A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma by Shaked, Yuval, Harel, Michal, Issler, Eran, Fremder, Ella, Jacob, Eyal, Dahan, Nili, Bar, Haim, Halaban, Ruth, Sznol, Mario, Sharon, Ofer

“…Abstract only 10037 Background: Immune checkpoint inhibitor-based immunotherapies that target CTLA-4 and the PD-1/PD-L1 axis have revolutionized the treatment…”
Get full text

Abstract LB-401: A proteomics-based biomarker discovery platform for predicting clinical response to immune checkpoint inhibitor therapy in non-small cell lung cancer by Harel, Michal, Khononov, Irena, Issler, Eran, Lahav, Coren, Fremder, Ella, Jacob, Eyal, Dahan, Nili, Raviv, Ziv, Shkedy, Avishag, Jacob, Reema, Dicker, Adam, Bar, Haim, Sharon, Ofer, Shaked, Yuval

“…Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm for non-small cell lung cancer (NSCLC) due to their unprecedented rates of durable…”
Get full text